Stevanato Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Stevanato Group yıllık ortalama 11.6% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 11.7% annual. Gelirler growing yılda ortalama 13.5% oranında artmaktadır. Stevanato Group'in özkaynak karlılığı 8.7% ve net marjı 10.5%'dir.

Anahtar bilgiler

11.6%

Kazanç büyüme oranı

9.2%

EPS büyüme oranı

Life Sciences Sektör Büyümesi21.5%
Gelir büyüme oranı13.5%
Özkaynak getirisi8.7%
Net Marj10.5%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think

Nov 12
Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think

Recent updates

Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement

Nov 13

Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think

Nov 12
Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think

Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models

Nov 08
Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models

We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt

Oct 23
We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt

Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?

Aug 21
Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?

Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump

Jul 25
Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump

Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?

Jul 23
Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?

Stevanato: Destock Pressures, Long-Term Upside

May 29

Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 12
Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion

May 07
Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion

Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations

Mar 15
Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations

Stevanato: Destocking And Valuation Risk (Rating Downgrade)

Mar 12

Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 09
Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value

Stevanato: Guidance Reiterated And Supportive Revenue Growth

Nov 22

Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$31.6 Based On Its Intrinsic Value?

Oct 22
Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$31.6 Based On Its Intrinsic Value?

Stevanato: Secular Tailwinds In Biologics Support Downstream Demand

Sep 15

Stevanato Group: Undeniable Quality, But Lacking Upside

Jun 14

Stevanato Group S.p.A. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next

Mar 05
Stevanato Group S.p.A. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next

Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma

Jan 24

There's Reason For Concern Over Stevanato Group S.p.A.'s (NYSE:STVN) Price

Dec 28
There's Reason For Concern Over Stevanato Group S.p.A.'s (NYSE:STVN) Price

Stevanato Group Non-GAAP EPS of $0.14 beats by $0.01, revenue of $245.3M in-line

Nov 08

An Intrinsic Calculation For Stevanato Group S.p.A. (NYSE:STVN) Suggests It's 49% Undervalued

Aug 01
An Intrinsic Calculation For Stevanato Group S.p.A. (NYSE:STVN) Suggests It's 49% Undervalued

A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)

Apr 19
A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)

Gelir ve Gider Dağılımı

Stevanato Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NYSE:STVN Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 241,09411511635
30 Jun 241,08812311338
31 Mar 241,08313611337
31 Dec 231,08514611436
30 Sep 231,05714911736
30 Jun 231,03114711735
31 Mar 231,01014311735
31 Dec 2298414311234
30 Sep 2292413910033
30 Jun 228931229533
31 Mar 228631258631
31 Dec 218441348330
30 Sep 218181238225
30 Jun 217611217922
31 Mar 217181087919
31 Dec 20662797917
31 Dec 1953739778

Kaliteli Kazançlar: STVN yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: STVN 'nin mevcut net kar marjları (10.5%) geçen yılın (14.1%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: STVN şirketinin kazancı son 5 yılda yılda 11.6% oranında arttı.

Büyüme Hızlandırma: STVN 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: STVN geçtiğimiz yıl negatif kazanç büyümesine ( -22.9% ) sahipti ve bu da onu Life Sciences sektör ortalamasıyla ( -4.7% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: STVN 'nin Özsermaye Getirisi ( 8.7% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin